About Us
Our Science & Programs
Our Technology & Manufacturing
Collaborations
Join Us
中文
About Us
Our Science & Programs
Our Technology & Manufacturing
Collaborations
Join Us
中文
News
2024-09-02
Skyline Therapeutics’ Novel Gene Therapy SKG1108 Receives FDA Orphan Drug Designation for Retinitis Pigmentosa
2024-05-07
Skyline Therapeutics Presents Multiple New Data at ASGCT 2024
2023-12-12
Skyline Therapeutics Receives China NMPA’s Approval of IND for SKG0201, a Novel SMN1 Gene Replacement Therapy Candidate for Spinal Muscular Atrophy (SMA)
2023-10-19
Skyline Therapeutics Receives China NMPA's Approval of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration
2023-07-03
Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration
2023-05-17
Skyline Therapeutics Brings Multiple Data Presentations to ASGCT 2023
2023-05-03
Skyline Therapeutics to Present at the ASGCT 26th Annual Meeting
2022-12-16
Skyline Therapeutics’ Novel AAV Gene Therapy for Ocular Disease Enters Clinical Trial
2022-01-10
China Eye Valley and Skyline Therapeutics sign memorandum of understanding to jointly advance ocular gene therapy practices
2022-01-01
Skyline announces Chief Development Officer as it advances multiple innovative research programs towards clinical stage
2021-12-17
BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases
2021-09-28
Skyline’s GMP manufacturing plant successfully completes large-scale high-quality viral vector production
2020-08-17
Geneception (now Skyline Therapeutics) R&D center launches in Zhangjiang Science City, equipped with cutting-edge gene therapy platforms